Physician

Don Luong, M.D.

According to 2025 Medicare claims, Don Luong, M.D. (NPI: 1992904379) practices hematology/oncology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33777-1206.

Luong's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 904 traditional Medicare patients, billed 222,774 HCPCS/CPT codes, and received $2,558,479 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,448 prescription claims across 304 beneficiaries totaling $4,095,739 in drug costs, led by Revlimid (Lenalidomide). DME data shows 59 claims. Open Payments data shows 190 records totaling $4,783. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,111,038 to $4,095,739. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,072	278,608	$2,833,030
2016	1,285	357,345	$4,179,772
2017	1,377	383,703	$4,593,963
2018	1,414	492,486	$5,425,575
2019	1,384	445,231	$5,553,911
2020	1,137	359,441	$4,863,004
2021	1,052	248,221	$4,136,068
2022	1,047	307,352	$3,993,813
2023	1,005	285,165	$3,287,795
2024	904	222,774	$2,558,479

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	267	1,435	$1,111,038
2016	257	1,325	$1,899,524
2017	258	1,354	$1,727,708
2018	257	1,302	$2,146,930
2019	268	1,313	$2,491,848
2020	264	1,153	$2,124,189
2021	252	1,111	$2,279,338
2022	266	1,268	$2,819,503
2023	281	1,320	$3,132,037
2024	304	1,448	$4,095,739

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	37	204	$11,190
2016	N/R	127	$15,478
2017	N/R	46	$10,031
2018	N/R	72	$8,565
2019	N/R	63	$6,105
2020	N/R	94	$15,032
2021	N/R	28	$3,743
2022	N/R	83	$13,182
2023	N/R	73	$5,134
2024	N/R	59	$3,062

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	344	962	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	402	638	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	166	214	$13
36415	Insertion of needle into vein for collection of blood sample	716	2,483	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	703	2,696	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	49	1,372	$920,252
Cabometyx	Cabozantinib S-Malate	15	450	$384,996
Imbruvica	Ibrutinib	23	644	$364,142
Calquence	Acalabrutinib Maleate	18	540	$275,889
Pomalyst	Pomalidomide	13	364	$221,602

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	11	$1,617
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$611
J8700	Temozolomide, oral, 5 mg	N	N/R	12	$559
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	18	$276

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	190	$4,783	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Don Luong, M.D.?

Tedicare shows public-source Medicare data for Don Luong, M.D. (NPI 1992904379), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Don Luong, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Don Luong, M.D.?

Don Luong, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Don Luong, M.D. have Open Payments data?

Don Luong, M.D. has 190 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.